True North Labs

Author: labstruenorth@gmail.com

  • Gilead’s $1.3B Bet on an Oral Peptide Signals Growing Confidence in Immunology Treatments

    In a move that underscores the growing confidence major pharmaceutical companies have in peptide-based therapeutics, Gilead Sciences has announced a $1.3 billion deal to acquire rights to an oral peptide drug candidate designed to treat immunology-related conditions. The investment positions the compound as a potential competitor to an existing immunology pill from Johnson & Johnson, signaling that peptide science continues to attract serious capital and attention from industry leaders.

    Oral peptide formulations represent an exciting frontier in drug development. Historically, peptides have required injection because they can break down in the digestive system before reaching their target. Advances in formulation technology have made it increasingly possible to deliver peptide therapies in pill form, which could make treatments more convenient and accessible for patients who might otherwise need regular injections.

    Gilead’s willingness to commit over a billion dollars to this compound reflects broader optimism in the biotech and pharmaceutical sectors about the therapeutic potential of peptides for complex conditions like immune and inflammatory disorders. Major acquisitions of this scale typically follow careful due diligence, suggesting that the underlying science and early data supporting this peptide candidate have impressed industry experts enough to justify significant financial backing.

    This kind of investment also tends to accelerate research and development timelines. With substantial resources behind it, the oral peptide candidate may move through further clinical evaluation more efficiently, potentially bringing new treatment options to patients sooner. Competition in the immunology space, especially between innovative peptide-based approaches and existing treatments, can also drive continued innovation and improvements in patient care options.

    For the broader peptide therapeutics field, deals like this one serve as an encouraging signal. They demonstrate that pharmaceutical companies see long-term value and viability in peptide-based drug development, which could pave the way for increased research funding and more oral peptide options across various therapeutic areas in the future.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill – MedCity News

  • Gilead Invests $1.3B in Promising Oral Peptide Therapy Targeting IL-23

    In a significant vote of confidence for peptide-based medicine, biopharmaceutical giant Gilead Sciences has announced a licensing deal worth $1.3 billion upfront to secure rights to an experimental oral peptide developed by PepStar. The peptide targets interleukin-23 (IL-23), a protein involved in several inflammatory and autoimmune conditions, and is designed to compete with existing injectable biologics in this therapeutic space.

    What makes this development particularly exciting for the peptide field is the oral delivery format. IL-23 inhibitors have traditionally been delivered via injection, requiring patients to administer or receive shots on a regular schedule. An effective oral peptide alternative could offer a more convenient treatment option for patients managing chronic inflammatory conditions, potentially improving treatment adherence and quality of life.

    This deal also reflects the broader momentum building behind oral peptide technology as a scientific discipline. Historically, peptides have faced challenges with oral bioavailability due to degradation in the digestive system, which is why injectable formulations have dominated this class of therapeutics. Major pharmaceutical investments like this one suggest that advances in peptide engineering and formulation science are successfully overcoming these longstanding hurdles.

    Gilead’s substantial upfront commitment signals strong institutional confidence in both the specific molecule and the underlying oral peptide platform technology. Such investments often accelerate further research and development, potentially paving the way for additional oral peptide candidates targeting other therapeutic areas in the future. As the peptide therapeutics landscape continues to evolve, partnerships of this scale help validate the scientific and commercial viability of this approach.

    This article is for informational purposes only and does not constitute medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde – Fierce Biotech

  • New Pediatric Trial Launches to Test Sonrotoclax for Relapsed Childhood Leukemia

    A new clinical trial has opened to study sonrotoclax (BGB-11417) in children and adolescents facing relapsed or refractory acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL). These are forms of blood cancer that can be especially challenging to treat once they return after initial therapy or fail to respond, making new investigational approaches like this one meaningful for families and care teams searching for additional options.

    The trial will evaluate sonrotoclax in combination with other established anti-cancer medicines, with researchers closely tracking safety, tolerability, and how the body absorbs, processes, and clears the drug. Participants will undergo regular monitoring, including physical exams, blood tests, and heart health checks, ensuring that safety remains a central focus throughout the study. Researchers will also assess how well the combination therapy helps reduce or eliminate leukemia in these young patients.

    What makes this study particularly encouraging is its focus on a patient population that often has limited treatment pathways. By specifically designing a trial for children and adolescents—rather than relying solely on data from adult studies—researchers aim to generate dedicated safety and efficacy information for this age group. Participants will continue treatment for as long as it provides benefit and side effects remain manageable, reflecting a patient-centered approach to care.

    Early-phase trials like this one play a critical role in the broader drug development pipeline. They help determine whether a promising compound can be safely combined with existing therapies and whether it shows signals of effectiveness that could support larger studies down the road. For families affected by pediatric leukemia, the launch of this trial represents another step forward in the ongoing effort to expand treatment possibilities for relapsed or hard-to-treat cases.

    As with all clinical research, results will take time to emerge, and enrollment and outcomes will be closely monitored by the research team. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia

  • New Phase 3 Trial Explores Shorter Treatment Path for Drug-Resistant Tuberculosis

    A new Phase 3 clinical trial has begun enrolling participants to evaluate treatment regimens containing quabodepistat, an investigational compound being studied for its potential to help combat drug-resistant tuberculosis (TB). This randomized, multicenter study represents an important step forward in the ongoing effort to find faster and more effective treatments for one of the world’s most persistent infectious diseases.

    The trial is structured around two patient cohorts based on whether their TB strain is susceptible or resistant to fluoroquinolone antibiotics. In the fluoroquinolone-susceptible group, researchers will compare a shortened four-month experimental regimen combining bedaquiline, pretomanid, quabodepistat, and moxifloxacin against the current six-month standard-of-care combination. If successful, this could mean patients spend two fewer months undergoing treatment, a meaningful improvement for quality of life and treatment adherence.

    For participants with fluoroquinolone-resistant TB, a six-month quabodepistat-based regimen will be compared to existing therapy. Including this harder-to-treat population is especially valuable, as drug-resistant TB strains have historically posed some of the greatest challenges in infectious disease treatment, often requiring longer and more complex drug combinations.

    With approximately 532 participants planned across both cohorts, the study is designed with rigorous safeguards, including a blinded Endpoint Adjudication Committee that will independently confirm treatment outcomes. This level of scientific oversight reflects a strong commitment to generating reliable, trustworthy data that could eventually inform updated treatment guidelines for drug-resistant pulmonary TB worldwide.

    Shortening TB treatment duration while maintaining or improving efficacy has long been a goal for researchers and public health officials, as longer treatment courses can strain healthcare systems and make it harder for patients to complete their full regimen. Trials like this one offer hope that new drug combinations may soon make treatment more manageable for patients facing this serious disease.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

  • Arch Biopartners Expands Phase 2 LSALT Peptide Trial to the United States

    Arch Biopartners has announced plans to expand its ongoing Phase 2 clinical trial evaluating its LSALT peptide, extending the study’s reach into the United States. This geographic expansion represents a meaningful milestone for the company’s drug development program, as it opens the door to a larger and more diverse pool of trial participants.

    LSALT peptide has been under investigation for its potential therapeutic applications, and the decision to broaden recruitment into the U.S. market signals growing confidence in the trial’s progress and design. Expanding a trial internationally often reflects positive momentum, as companies typically pursue such growth when early data and operational experience support scaling up patient enrollment.

    Bringing U.S. clinical sites into the fold can accelerate the pace of enrollment, which is often one of the most time-consuming aspects of clinical research. A broader participant base across multiple countries can also help generate more robust and generalizable data, potentially strengthening the overall evidence package as the peptide moves through the development pipeline.

    For patients and the broader peptide research community, news like this underscores the continued interest in peptide-based therapeutics and the steady progress being made in bringing novel treatments through the rigorous phases of clinical testing. Expansions of this nature also reflect growing collaboration between biotech companies and regulatory frameworks that support multi-national trial designs.

    As Arch Biopartners moves forward with this expanded trial footprint, the peptide research field continues to demonstrate steady advancement. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Arch Biopartners to Expand Ongoing Phase 2 LSAT Peptide Trial to The US – Yahoo Finance

  • New Peptide Probe Shows Promise for Targeted Tumor Imaging

    New Peptide Probe Shows Promise for Targeted Tumor Imaging

    A team of researchers has unveiled a novel peptide-based imaging probe designed to target CD147, a protein frequently overexpressed on the surface of various tumor cells. Published through Wiley & Sons, the study outlines both the development of this antagonistic peptide probe and the results of an initial pilot clinical study, marking an encouraging step forward in the field of molecular imaging for cancer detection.

    CD147, also known as Basigin, has long been studied for its role in tumor progression and its potential as a biomarker across several cancer types. By designing a peptide that specifically binds to and blocks CD147, researchers aimed to create an imaging agent that could help clinicians visualize tumors with greater specificity than some conventional imaging techniques. The ‘antagonistic’ nature of the peptide suggests it may also interact with CD147’s biological function, offering a dual role as both a diagnostic tool and a potential area for further therapeutic exploration.

    The pilot clinical study represents an important early-stage validation of this approach, moving the technology from laboratory development into real-world testing. While details of the pilot are preliminary, the fact that researchers have progressed to human-focused clinical evaluation is a meaningful milestone, indicating that the probe has cleared initial safety and feasibility hurdles necessary for such studies to proceed.

    Improved tumor imaging tools like this peptide probe could eventually support more accurate cancer detection, better treatment planning, and more precise monitoring of therapeutic response. Peptide-based imaging agents are especially promising because they can often be designed with high specificity for molecular targets, potentially reducing background signal and improving image clarity compared to some traditional contrast agents.

    As with all early-stage pilot studies, further research involving larger patient populations will be needed to confirm the probe’s effectiveness, safety profile, and practical clinical value. Nonetheless, this development adds to the growing body of innovative peptide research aimed at improving how clinicians detect and understand cancer. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging – Wiley & Sons

  • FDA-Approved Peptide Therapies Offer New Hope for Weight Management

    FDA-Approved Peptide Therapies Offer New Hope for Weight Management

    Peptide-based medications have become one of the most significant developments in weight management in recent years, with the U.S. Food and Drug Administration approving several injectable peptide therapies designed to help patients lose weight and improve related health markers. These approvals reflect a growing body of clinical research showing that certain peptides can meaningfully support weight loss when used as part of a comprehensive treatment plan that includes diet and lifestyle changes.

    Unlike many weight-loss approaches of the past, these FDA-cleared peptide treatments have gone through rigorous clinical trials examining their safety and effectiveness over extended periods. Regulatory approval means the treatments have met strict standards for manufacturing quality, consistent dosing, and demonstrated benefit-to-risk ratios, giving both physicians and patients more confidence when considering these options.

    For many individuals struggling with obesity or weight-related health conditions, the arrival of FDA-sanctioned peptide options represents a meaningful expansion of available tools. Having medications that go through the FDA’s approval pathway, rather than relying solely on compounded or unregulated products, helps ensure that patients are accessing treatments backed by scientific evidence and manufacturing oversight.

    The broader peptide research field continues to build on this momentum, with ongoing studies exploring how these molecules interact with appetite regulation, metabolism, and other physiological processes. As more data emerges, researchers and clinicians are gaining a clearer picture of how peptide therapies might fit into long-term strategies for managing weight and supporting overall metabolic health.

    This growing acceptance of peptide-based treatments within mainstream, regulated medicine is an encouraging sign for the field as a whole, potentially paving the way for continued innovation and further approvals down the road. As always, individuals interested in these treatments should consult with a qualified healthcare provider to determine what options may be appropriate for their individual circumstances. This article is for informational purposes only and does not constitute medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: fda approved peptides for weight loss – polskieradio.pl

  • Eli Lilly Extends Compassionate Access to Obesity Medication for Older Patient

    Eli Lilly Extends Compassionate Access to Obesity Medication for Older Patient

    A recent case involving Eli Lilly has drawn attention to the ways pharmaceutical companies can extend access to promising obesity treatments beyond standard clinical trial enrollment. According to reporting from STAT, the company granted expanded access to one of its obesity drugs to a 79-year-old patient, a decision that sheds light on the compassionate use pathways available for individuals who may not otherwise qualify for ongoing trials.

    Expanded access programs, sometimes called compassionate use, allow pharmaceutical companies to provide investigational treatments to patients outside of formal clinical trials when there is a reasonable expectation of benefit and no comparable alternative exists. These programs are especially meaningful for older adults, who are often excluded from standard trial populations due to age-related eligibility criteria, even though they may stand to benefit significantly from emerging therapies.

    The obesity drug landscape has advanced rapidly in recent years, with GLP-1 and related peptide-based medications showing substantial results in weight management and metabolic health. As these therapies continue to demonstrate strong safety and efficacy profiles in broader populations, cases like this one highlight growing interest in ensuring that older adults are not left behind simply because of age-based trial restrictions.

    This development also reflects a broader trend among drug makers to consider more flexible, patient-centered approaches to access particularly for conditions like obesity that carry significant health implications across all age groups. As research continues to expand, discussions around who can benefit from these treatments and how access can be broadened responsibly are likely to remain an important part of the conversation in metabolic medicine.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? – STAT

  • FDA Advisory Committee Signals Support for Expanded Access Pathway for BPC-157 and KPV

    FDA Advisory Committee Signals Support for Expanded Access Pathway for BPC-157 and KPV

    In a move that has generated optimism across the peptide research and wellness community, an FDA advisory committee recently voted in favor of exploring an expanded regulatory pathway for two closely watched compounds: BPC-157 and KPV. The vote, highlighted in a statement from The Precision Peptide Company, represents a potential turning point for how these peptides could be evaluated and eventually accessed within a more defined regulatory framework.

    BPC-157 and KPV have attracted significant attention in recent years for their roles in ongoing research related to tissue support and inflammatory response pathways. Despite this interest, both compounds have existed in a regulatory gray area, leaving researchers, clinicians, and companies eager for clearer guidance. An advisory committee vote in favor of an expanded pathway suggests that regulators are taking a more active and constructive look at how these peptides might be formally studied, manufactured, and potentially made available under appropriate oversight.

    For the peptide industry, this kind of regulatory engagement is an encouraging sign. A structured pathway could pave the way for more rigorous clinical research, higher manufacturing standards, and greater transparency for consumers and healthcare providers alike. Companies like The Precision Peptide Company view this as validation of years of advocacy for sensible, science-based regulation that balances innovation with safety.

    While an advisory committee vote is not the same as final FDA approval or policy implementation, it often serves as an important early indicator of the agency’s direction. Should this expanded pathway move forward through subsequent regulatory steps, it could open the door to more formal clinical trials, better-defined manufacturing standards, and increased confidence for both researchers and the public regarding the quality and consistency of these peptides.

    This development is being closely watched by stakeholders across the peptide research space, who see it as a potential model for how emerging compounds can be responsibly integrated into the broader regulatory system. As the process continues, further announcements are expected to clarify next steps and timelines.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV – TMX Newsfile

  • FDA Advisory Panel to Explore Expanding Access to Certain Peptides

    In a development that has the peptide community buzzing with cautious optimism, the U.S. Food and Drug Administration has announced plans to convene an advisory panel dedicated to discussing broader access to certain peptide compounds. This meeting signals that regulators are actively engaging with the evolving landscape of peptide-based therapies and considering pathways that could make these compounds more accessible.

    Peptides have garnered significant attention in recent years for their potential applications across numerous areas of health and wellness, from metabolic support to recovery and longevity-focused research. However, regulatory clarity has often lagged behind scientific interest, leaving many promising compounds in a gray area that can limit both research opportunities and patient access. A dedicated FDA panel discussion represents a meaningful step toward addressing these gaps.

    What makes this news particularly encouraging is the collaborative nature of the process. Advisory panels typically bring together experts from clinical, scientific, and regulatory backgrounds to evaluate evidence and weigh potential benefits against safety considerations. This kind of structured dialogue is often a precursor to more defined regulatory pathways, which can ultimately benefit both the medical community and patients seeking legitimate, well-regulated options.

    For the broader peptide industry, including researchers, compounding pharmacies, and healthcare providers, a clearer regulatory framework could mean more confidence in bringing beneficial peptide therapies to those who could benefit from them. It may also encourage further investment in research and quality manufacturing standards, as companies gain better insight into what the FDA expects moving forward.

    While the specific outcomes of this panel discussion remain to be seen, the willingness of the FDA to engage directly with questions of peptide access is a positive signal. It suggests regulators recognize the growing role peptides play in modern medicine and research, and are working to ensure that access decisions are grounded in careful, evidence-based evaluation. True North Labs will continue to monitor developments from this panel and provide updates as more information becomes available.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance specific to your situation.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA panel will meet to discuss allowing broader access to certain peptides – STAT